Myelodysplastic/Myeloproliferative Syndromes
Treosulfan + Fludarabine + TBI for Allo HCT for AML and MDS (FHCRC-2272)
Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Investigator: Boglarka Gyurkocza, MD; Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD); Status: Closed; Study ID: NCT00860574
Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care
Investigator: Bart Lee Scott, MD; Conditions: Polycythemia Vera; Status: Recruiting; Study ID: NCT01243944
Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine
Investigator: Bart Lee Scott, MD; Conditions: Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01241500
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Under Age 60 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome
Investigator: Pamela Becker, MD, PhD; Conditions: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS); Status: Closed; Study ID: NCT01101880
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Closed; Study ID: NCT01141725
A Phase-3, Multi-Center, Randomized, Doubleblind, Placebo-Controlled, Parallel-Group Study To Compare Efficacy And Safety Of Pomalidomide In Subjects With Myeloproliferative Neoplasm, Associated Myelofibrosis And Red Blood Cell-Transfusiondependence
Investigator: Joachim Deeg, MD; Conditions: Hematologic Malignancies; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD); Status: Closed; Study ID: NCT01178281
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Investigator: Fred Appelbaum, MD; Conditions: Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT00843882
Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML
Investigator: Roland B. Walter, MD, PhD; Conditions: Myelodysplastic Syndromes, Leukemia; Status: Recruiting; Study ID: NCT01235572
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate
Investigator: John M. Pagel, MD; Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome; Status: Recruiting; Study ID: NCT00988715
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML
Investigator: Derek L. Stirewalt, MD; Conditions: Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01607645
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01729845
Join Us On